NLTX Annual CFI
-$59.13 M
-$55.87 M-1712.26%
31 December 2022
Summary:
As of February 5, 2025, NLTX annual cash flow from investing activities is -$59.13 million, with the most recent change of -$55.87 million (-1712.26%) on December 31, 2022. During the last 3 years, it has fallen by -$58.45 million (-8495.06%).NLTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Quarterly CFI
-$1.61 M
-$1.20 M-292.70%
30 September 2023
Summary:
As of February 5, 2025, NLTX quarterly cash flow from investing activities is -$1.61 million, with the most recent change of -$1.20 million (-292.70%) on September 30, 2023. Over the past year, it has increased by +$26.24 million (+94.20%).NLTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX TTM CFI
$17.15 M
+$26.24 M+288.69%
30 September 2023
Summary:
As of February 5, 2025, NLTX TTM cash flow from investing activities is $17.15 million, with the most recent change of +$26.24 million (+288.69%) on September 30, 2023. Over the past year, it has increased by +$85.14 million (+125.22%).NLTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1712.3% | +94.2% | +125.2% |
| 3 y3 years | -8495.1% | -231.4% | +830.3% |
| 5 y5 years | -192.4% | -153.4% | +2592.4% |
NLTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -192.4% | -105.1% | -83.0% |
Neoleukin Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$1.61 M(+292.7%) | $17.15 M(-288.7%) |
| June 2023 | - | -$411.00 K(-103.8%) | -$9.09 M(-81.1%) |
| Mar 2023 | - | $10.71 M(+26.4%) | -$47.98 M(-18.9%) |
| Dec 2022 | -$59.13 M(+1712.3%) | $8.47 M(-130.4%) | -$59.13 M(-13.0%) |
| Sept 2022 | - | -$27.85 M(-29.1%) | -$68.00 M(+66.9%) |
| June 2022 | - | -$39.30 M(+8594.5%) | -$40.73 M(+1451.2%) |
| Mar 2022 | - | -$452.00 K(+14.1%) | -$2.63 M(-19.5%) |
| Dec 2021 | -$3.26 M(+47.0%) | -$396.00 K(-32.5%) | -$3.26 M(-7.3%) |
| Sept 2021 | - | -$587.00 K(-50.7%) | -$3.52 M(+2.9%) |
| June 2021 | - | -$1.19 M(+9.4%) | -$3.42 M(+6.8%) |
| Mar 2021 | - | -$1.09 M(+66.8%) | -$3.20 M(+44.3%) |
| Dec 2020 | -$2.22 M(+222.5%) | -$653.00 K(+34.1%) | -$2.22 M(-5.5%) |
| Sept 2020 | - | -$487.00 K(-49.9%) | -$2.35 M(+32.9%) |
| June 2020 | - | -$972.00 K(+808.4%) | -$1.77 M(+122.3%) |
| Mar 2020 | - | -$107.00 K(-86.3%) | -$795.00 K(+15.6%) |
| Dec 2019 | -$688.00 K(-101.2%) | -$782.00 K(-931.9%) | -$688.00 K(-831.9%) |
| Sept 2019 | - | $94.00 K(>+9900.0%) | $94.00 K(-96.9%) |
| June 2019 | - | $0.00(0.0%) | $3.02 M(-88.4%) |
| Mar 2019 | - | $0.00(0.0%) | $25.99 M(-53.5%) |
| Dec 2018 | $55.95 M | $0.00(-100.0%) | $55.95 M(-22.8%) |
| Sept 2018 | - | $3.02 M(-86.9%) | $72.44 M(-28.2%) |
| June 2018 | - | $22.97 M(-23.3%) | $100.89 M(+7.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $29.96 M(+81.8%) | $94.08 M(+47.0%) |
| Dec 2017 | $64.01 M(-233.2%) | $16.48 M(-47.6%) | $64.01 M(+2167.5%) |
| Sept 2017 | - | $31.48 M(+94.8%) | $2.82 M(-109.8%) |
| June 2017 | - | $16.16 M(<-9900.0%) | -$28.71 M(-42.8%) |
| Mar 2017 | - | -$108.00 K(-99.8%) | -$50.16 M(+4.4%) |
| Dec 2016 | -$48.06 M(+1.1%) | -$44.70 M(>+9900.0%) | -$48.06 M(-30.4%) |
| Sept 2016 | - | -$52.00 K(-99.0%) | -$69.03 M(+9.7%) |
| June 2016 | - | -$5.30 M(-365.4%) | -$62.92 M(+22.0%) |
| Mar 2016 | - | $2.00 M(-103.0%) | -$51.60 M(+8.5%) |
| Dec 2015 | -$47.53 M(+101.6%) | -$65.68 M(-1184.0%) | -$47.53 M(-296.4%) |
| Sept 2015 | - | $6.06 M(+0.5%) | $24.20 M(+18.9%) |
| June 2015 | - | $6.03 M(-0.5%) | $20.34 M(-216.2%) |
| Mar 2015 | - | $6.06 M(+0.1%) | -$17.51 M(-25.7%) |
| Dec 2014 | -$23.57 M(+792.9%) | $6.05 M(+174.3%) | -$23.57 M(-27.3%) |
| Sept 2014 | - | $2.21 M(-106.9%) | -$32.44 M(-6.3%) |
| June 2014 | - | -$31.83 M(>+9900.0%) | -$34.62 M(+1186.9%) |
| Mar 2014 | - | -$4000.00(-99.9%) | -$2.69 M(+1.9%) |
| Dec 2013 | -$2.64 M(>+9900.0%) | -$2.81 M(<-9900.0%) | -$2.64 M(-1613.8%) |
| Sept 2013 | - | $26.50 K(-74.0%) | $174.40 K(+17.9%) |
| June 2013 | - | $101.80 K(+120.8%) | $147.90 K(+220.8%) |
| Mar 2013 | - | $46.10 K | $46.10 K |
| Dec 2012 | -$6400.00 | - | - |
FAQ
- What is Neoleukin Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual CFI year-on-year change?
- What is Neoleukin Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly CFI year-on-year change?
- What is Neoleukin Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics TTM CFI year-on-year change?
What is Neoleukin Therapeutics annual cash flow from investing activities?
The current annual CFI of NLTX is -$59.13 M
What is the all time high annual CFI for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual cash flow from investing activities is $64.01 M
What is Neoleukin Therapeutics annual CFI year-on-year change?
Over the past year, NLTX annual cash flow from investing activities has changed by -$55.87 M (-1712.26%)
What is Neoleukin Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of NLTX is -$1.61 M
What is the all time high quarterly CFI for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly cash flow from investing activities is $31.48 M
What is Neoleukin Therapeutics quarterly CFI year-on-year change?
Over the past year, NLTX quarterly cash flow from investing activities has changed by +$26.24 M (+94.20%)
What is Neoleukin Therapeutics TTM cash flow from investing activities?
The current TTM CFI of NLTX is $17.15 M
What is the all time high TTM CFI for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high TTM cash flow from investing activities is $100.89 M
What is Neoleukin Therapeutics TTM CFI year-on-year change?
Over the past year, NLTX TTM cash flow from investing activities has changed by +$85.14 M (+125.22%)